Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 0.00 | 0.00 | 0.41 | 0.00 | 0.00 | 0.21 | 2.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating costs | 0.39 | 0.50 | 0.86 | 0.27 | 0.37 | 0.54 | 2.90 | 0.29 | 0.75 | 1.31 | 1.31 | 0.70 |
| EBITDA | -0.39 | -0.50 | -0.45 | -0.27 | -0.37 | -0.33 | -0.48 | -0.29 | -0.75 | -1.31 | -1.31 | -0.70 |
| EBITDA margin % | -109.76% | -157.14% | -19.83% | |||||||||
| Depreciation & amortisation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Finance costs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Non-operating income | 1.69 | 2.02 | 2.16 | 2.47 | 2.31 | 2.19 | 1.56 | 1.64 | 1.68 | 2.25 | 3.70 | 5.11 |
| Pre-tax profit | 1.30 | 1.52 | 1.71 | 2.20 | 1.94 | 1.86 | 1.08 | 1.35 | 0.93 | 0.94 | 2.39 | 4.35 |
| Effective tax rate % | 25.38% | 25.66% | 26.90% | 24.09% | 25.26% | 25.27% | 32.41% | 26.67% | 27.96% | 43.62% | 12.55% | 21.38% |
| Profit after tax | 0.97 | 1.14 | 1.25 | 1.66 | 1.44 | 1.39 | 0.73 | 0.99 | 0.68 | 0.53 | 2.09 | 3.42 |
| Earnings per share (Rs) | 0.79 | 0.93 | 1.02 | 1.36 | 1.18 | 1.14 | 0.60 | 0.81 | 0.56 | 0.43 | 1.71 | 2.79 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.05 | -0.20 | 0.00 | 0.34 | 2.63 | 0.00 | 0.00 |
| Operating costs | 0.93 | 0.98 | 1.69 | 1.18 | 1.39 | 1.88 | 2.54 | 1.73 | 2.08 | 4.09 | 3.63 | 4.07 |
| EBITDA | -0.93 | -0.98 | -1.69 | -1.18 | -1.39 | -1.93 | -2.74 | -1.73 | -1.74 | -1.46 | -3.63 | -4.07 |
| EBITDA margin % | -511.76% | -55.51% | ||||||||||
| Depreciation & amortisation | 1.02 | 1.02 | 0.97 | 0.80 | 0.57 | 0.12 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 |
| Finance costs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Non-operating income | 1.97 | 1.78 | 2.11 | 2.75 | 2.76 | 26.82 | 6.66 | 4.24 | 7.40 | 8.53 | 9.25 | 12.74 |
| Pre-tax profit | 0.02 | -0.22 | -0.55 | 0.77 | 0.80 | 24.77 | 3.91 | 2.50 | 5.65 | 7.06 | 5.61 | 8.61 |
| Effective tax rate % | -150.00% | 0.00% | 116.36% | 61.04% | 47.50% | 2.50% | 26.60% | 50.80% | 25.66% | 26.06% | 23.53% | |
| Profit after tax | 0.05 | -0.22 | -1.19 | 0.31 | 0.41 | 24.15 | 2.87 | 1.24 | 4.20 | 5.23 | 4.30 | 6.72 |
| Earnings per share (Rs) | 0.04 | -0.18 | -0.97 | 0.25 | 0.33 | 19.73 | 2.34 | 1.01 | 3.43 | 4.27 | 3.51 | 5.49 |
| Paid out as dividend % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Revenue CAGR | % | % | % | -100% | ||
| Profit CAGR | 56% | 14% | 58% | 48% | ||
| Share price CAGR | 38% | 83% | 161% | 561% | ||
| Average return on equity | 3% | 5% | 6% | 5% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net block (property, plant) | 8.40 | 7.42 | 6.40 | 5.43 | 4.27 | 3.70 | 0.11 | 0.10 | 0.09 | 0.09 | 0.05 | 0.02 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 27.50 | 28.01 | 29.79 | 10.21 | 5.93 | 3.69 | 8.69 | 8.82 | 8.23 | 8.91 | 2.04 | 1.97 |
| Current & other assets | 2.67 | 3.19 | 1.97 | 21.34 | 28.17 | 29.68 | 54.62 | 57.89 | 57.91 | 67.31 | 77.63 | 85.74 |
| Total assets | 38.57 | 38.62 | 38.16 | 36.98 | 38.37 | 37.07 | 63.42 | 66.81 | 66.23 | 76.31 | 79.72 | 87.73 |
| Share capital | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 |
| Reserves & surplus | 26.11 | 26.15 | 25.75 | 24.57 | 25.74 | 24.53 | 50.70 | 54.06 | 53.60 | 63.41 | 67.08 | 71.34 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other liabilities & provisions | 0.22 | 0.23 | 0.17 | 0.17 | 0.39 | 0.30 | 0.48 | 0.51 | 0.39 | 0.66 | 0.40 | 4.15 |
| Equity + liabilities | 38.57 | 38.62 | 38.16 | 36.98 | 38.37 | 37.07 | 63.42 | 66.81 | 66.23 | 76.31 | 79.72 | 87.73 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.94 | 1.08 | 0.55 | -19.79 | 10.34 | -0.63 | -27.72 | 21.91 | 1.22 | -39.31 | 36.00 | -2.89 |
| Investing cash flow | -1.21 | -0.26 | -1.51 | 19.78 | 5.73 | 0.67 | 23.06 | 0.60 | -0.94 | 5.12 | 6.02 | 1.65 |
| Free cash flow (after capex) | 0.94 | 1.04 | 0.55 | -19.79 | 10.53 | -0.63 | -1.79 | 21.91 | 1.22 | -39.31 | 36.53 | -1.31 |
| Financing cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net change in cash | -0.27 | 0.83 | -0.95 | -0.01 | 16.07 | 0.04 | -4.66 | 22.51 | 0.28 | -34.18 | 42.02 | -1.24 |
| Cash conversion (OCF / EBITDA) % | -121% | -116% | -56% | 1,165% | -897% | 0% | 1,401% | -853% | -132% | 2,182% | -2,618% | 47% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on capital employed % | 0.63% | 0.05% | -0.58% | -1.47% | 1.63% | 2.03% | 4.61% | 4.22% | 3.50% | 7.99% | 9.11% | 6.90% |
| Receivable days | 0.00 | 0.00 | 440.15 | 376.10 | ||||||||
| Inventory days | 35,770.00 | 32,485.00 | -511.00 | -273.75 | 0.00 | 0.00 | ||||||
| Payable days | 0.00 | 0.00 | ||||||||||
| Cash cycle (days) | -511.00 | -273.75 | 440.15 | 376.10 | ||||||||
| Working capital days | 311,418.00 | 42,705.00 | 71,421.91 | 4,856.03 |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter group % | 51.68% | 51.68% | 51.68% | 51.68% | 51.68% | 51.68% | 56.45% | 56.45% | 56.45% | 56.45% | 56.45% | 56.45% |
| Foreign investors % | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Domestic institutions % | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Retail & others % | 48.29% | 48.29% | 48.30% | 48.29% | 48.29% | 48.29% | 43.51% | 43.52% | 43.51% | 43.52% | 43.52% | 43.52% |
| Shareholder count | 13,603 | 13,615 | 13,813 | 13,681 | 13,647 | 13,835 | 13,843 | 13,767 | 13,680 | 13,339 | 13,145 | 13,048 |
Fundamentals
Market value₹ 508 Cr.
Last price₹ 415
P/E (trailing)75.6
Book value / share₹ 68.3
Return on capital6.90 %
Return on equity5.29 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)-100%
Profit CAGR (TTM)48%
Standalone figures.
Valuation
Market capRs 508 Cr
Enterprise valueRs 466 Cr
P/E (TTM)75.62x
Price to book6.08x
EV / EBITDA54.03x
EV / EBIT54.09x
Earnings yield1.32%
P/E, 3-year average20.76x
P/B, 3-year average1.12x
P/E, 5-year average18.06x
P/B, 5-year average0.82x
Profitability
ROE5.28%
ROCE6.89%
ROA5.14%
ROE, 3-year average5.99%
ROCE, 3-year average8.00%
ROA, 3-year average5.91%
ROE, 5-year average4.86%
ROCE, 5-year average6.76%
ROA, 5-year average4.80%
ROIC (approx.)16.00%
Tax rate23.53%
Other income / net worth11.07%
Growth
Profit growth (latest year)-17.78%
Profit CAGR, 3 years51.36%
Profit CAGR, 5 years-29.19%
Profit growth QoQ63.64%
Profit growth YoY (latest quarter)245.45%
Per share
EPS (TTM)Rs 5.49
EPS (latest year)Rs 3.51
EPS (latest quarter)Rs 2.79
EPS, 3-year averageRs 3.74
EPS, 5-year averageRs 2.92
Book value per shareRs 68.28
Cash flow per shareRs -2.36
Leverage
Cash and bankRs 42 Cr
Net debtRs -42 Cr
Net debt / EBITDA-4.92x
Owners' fund to total sources95.27%
Cash flow
Operating cash flow (latest year)Rs -3 Cr
Investing cash flow (latest year)Rs 2 Cr
Net change in cash (latest year)Rs -1 Cr
Statement figures
Operating profit (latest quarter)Rs -1 Cr
Other income (TTM)Rs 13 Cr
EBITDA (TTM)Rs 9 Cr
PBDT (TTM)Rs 9 Cr
Profit before tax (TTM)Rs 9 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 7 Cr
Net profit (latest year)Rs 4 Cr
Net profit (latest quarter)Rs 3 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 9 Cr
Share capitalRs 12 Cr
ReservesRs 71 Cr
Shareholders' fundsRs 84 Cr
Total assetsRs 88 Cr
Net blockRs 0 Cr
InvestmentsRs 2 Cr
ReceivablesRs 2 Cr
Other liabilitiesRs 4 Cr
Shares outstanding (crore)1.22
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 75.6 is at the 92th percentile of its own 7.4-year range
(median 23.9, low 1.0, high 97.6).
P/B 6.08 is at the 98th percentile (median 0.63).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 500422 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +3.8% | -2.8% | +6.6 pts |
| 1 month | +24.6% | -6.8% | +31.4 pts |
| 3 months | +21.4% | -7.6% | +29.0 pts |
| 3 years | +1671.1% | +14.2% | +1656.9 pts |
| 5 years | +1975.8% | +27.9% | +1947.9 pts |
Red flags
F-score 3 of 6| explain | Weak cash conversion Cash from operations was -45% of net profit over the last 3 years |
| look | Profit leans on other income Other income was 165% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹0 Cr.
Net profit ₹3 Cr +245.5%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Transchem Ltd?
Transchem Ltd (500422) has a market capitalisation of Rs 508 Cr. at the 2026-10-01 close.
What is the P/E ratio of Transchem Ltd?
Transchem Ltd trades at a P/E of 75.6 on trailing twelve-month profit, at the 2026-10-01 close.
What were Transchem Ltd's latest quarterly results?
In the Jun 2026 quarter, Transchem Ltd sales was Rs 0 Cr and net profit was Rs 3 Cr.